The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Ekterly JACE Pharma Pty Ltd
Product name
Ekterly
Sponsor
Accepted date
Oct-2024
Active ingredients
Sebetralstat
Proposed indication
Ekterly (sebetralstat) is for the treatment of hereditary angioedema (HAE) attacks (swelling in different parts of the body due to C1-inhibitor inactivity) in adults and adolescents aged 12 years and older.
Application type
A (new medicine)
Publication date
Oct-2024
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.